SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020

[July 17, 2014]

OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020

(M2 PressWIRE Via Acquire Media NewsEdge) Dublin - Research and Markets (http://www.researchandmarkets.com/research/n6jz3w/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020" report to their offering.


Individuals infected with DENV can present with a wide spectrum of symptoms, including fevers, retro-orbital pain, severe headache, muscle and joint pain, and rash. The severity of dengue fever ranges from asymptomatic cases, to classic dengue fever, and to dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) that have a mortality rate of 5%-15%. Because there are no marketed dengue-specific vaccines or therapeutics, current treatment strategies are limited to supportive care for those already infected with the virus, and vector control to reduce DENV transmission.

The near-universal failure of these measures to curtain transmission and reduce disease burden across the global marketplace - which for the purposes of this report is comprised of Brazil, India, Mexico, Singapore, and Thailand - has further enhanced the need for safe and effective vaccines. GlobalData expects the launch of the first dengue vaccines, led by Sanofi Pasteur's CYD-TDV and Takeda's DENVax, to revolutionize the treatment and prevention paradigm.

Key Findings - The dengue vaccine market in Brazil, India, Mexico, Singapore, and Thailand to grow from $69.6m in 2015 to $398.6m in 2020, at a compound annual growth rate (CAGR) of 41.8%. This rapid growth will be due to the expected incorporation of newly-launched dengue vaccines into routine immunization programs.

- KOLs interviewed by GlobalData expect the live-attenuated dengue vaccines - led by Sanofi Pasteur's CTD-TDV and Takeda's DENVax - to dominate the marketplace for the duration of the forecast period.

- GlobalData anticipates that firms will increasingly turn to innovative R&D strategies, in particular the exploration of alternative approaches to early-stage clinical trial design - such as the dengue human infection model (DHIM) - in order to increase developmental efficiency, minimize upfront risk, and gain a competitive advantage over rivals.

- Domestically-supplied vaccines, most notably Butantan Institute's TV-003 in Brazil and Panacea Biotech's/Biological E's TV-003 in India, are projected to limit market growth due to their low price relative to vaccines produced by privately-held foreign companies.

Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Surveillance, Prevention, and Control Measures 6 Unmet Needs Assessment and Opportunity Analysis 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/n6jz3w/opportunityanalyze CONTACT: Research and Markets, Laura Wood, Senior Manager.

press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Infectious Diseases (http://www.researchandmarkets.com/categories.asp?cat_id=121&campaign_id=n6jz3w) .

(c) 2014 M2 COMMUNICATIONS

[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.